We are live on ! Find out more
CTOR

Citius Oncology
CTOR

Fund managers haven’t disclosed any holdings of CTOR yet.

CTOR Hedge Fund Activity: Q1 2026 in Review

14 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Citius Oncology (CTOR) for Q1 2026, worth a combined $8.83M — up 29% from $6.86M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of CTOR and 3 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 7 added.

The largest buyer was Bank of America, adding an estimated $3.85M. The largest seller was OMERS Administration Corp, exiting entirely with an estimated $105K sold.

  • 14 institutional investors held Citius Oncology (CTOR) as of Q1 2026, down from 18 in Q4 2025.
  • Funds reported $8.83M of Citius Oncology stock for Q1 2026, up 29% quarter-over-quarter.
  • 3 funds opened new Citius Oncology positions in Q1 2026 and 6 closed out, a net change of -3 holders.
  • The largest Citius Oncology buyer in Q1 2026 was Bank of America, an estimated $3.85M added.
  • The largest Citius Oncology seller in Q1 2026 was OMERS Administration Corp, an estimated $105K sold.

Based on aggregated 13F filings for Q1 2026.